ReviewAnnals of translational medicine2015
Body fluid biomarkers in Alzheimer's disease.
Review in Annals of translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Voice biomarkers in middle and later adulthood as predictors of cognitive changes.Frontiers in psychology · 2024Article
- Voice biomarkers as indicators of cognitive changes in middle and later adulthood.Neurobiology of aging · 2022Article
- Non-Invasive Nasal Discharge Fluid and Other Body Fluid Biomarkers in Alzheimer's Disease.Pharmaceutics · 2022Review
- Recent Advancements in Electrochemical Biosensors for Alzheimer's Disease Biomarkers Detection.Current medicinal chemistry · 2021Review
- Mounting evidence of FKBP12 implication in neurodegeneration.Neural regeneration research · 2020Review
- Plasma Biomarkers: Potent Screeners of Alzheimer's Disease.American journal of Alzheimer's disease and other dementias · 2019Review
- Overview the effect of statin therapy on dementia risk, cognitive changes and its pathologic change: a systematic review and meta-analysis.Annals of translational medicine · 2018Article
- Tau in neurodegenerative disease.Annals of translational medicine · 2018Review
- Clinical aspects and biomarkers of Alzheimer's disease in Down syndrome.Free radical biology & medicine · 2018Review
- Spreading of Pathology in Alzheimer's Disease.Neurotoxicity research · 2017Review
- Extent of agreement between the body fluid model of Sysmex XN-20 and the manual microscopy method.Journal of clinical laboratory analysis · 2017Article
- Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2016Article
- Erratum to Body fluid biomarkers in Alzheimer's disease.Annals of translational medicine · 2016Article
- Differential levels of p75NTR ectodomain in CSF and blood in patients with Alzheimer's disease: a novel diagnostic marker.Translational psychiatry · 2015Article
- [Anesthesia and Alzheimer disease - Current perceptions].Brazilian journal of anesthesiology (Elsevier)Review
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A heterogeneous and slowly progressive disease with extracellular amyloid-β (Aβ) deposits and intracellular hyperphosphorylated tau protein aggregates, Alzheimer's disease (AD) is already a hard nut to crack, featured with cognitive decline and memory lapse. Body fluid biomarkers are proved to be useful in exploring further study of AD, might benefit for a full comprehension of the etiopathogenesis, an improved precision of the prognosis and diagnosis, and a positive response of treatments. The cerebrospinal fluid biomarkers Aβ, total tau, and hyperphosphorylated tau reflect the main pathologic changes of AD. We also review data from several novel biomarkers, such as, β-site APP cleaving enzyme 1, soluble amyloid precursor proteins α and β, soluble Aβ oligomers and so on, which are associated with the occurrence and deterioration of this disease and couldn't be ignored. The rationale for the clinical use of those biomarkers, the challenges faced with and the properties of the most appropriate biomarkers are also summarized in the paper. We aim to find several ideal biomarkers to improve the diagnosis and optimize the treatment respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.